Dyne Therapeutics, Inc.
DYN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $2,243 | $2,461 | $0 | $0 |
| Gross Profit | -$2,243 | -$2,461 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $281,406 | $210,762 | $142,760 | $121,308 |
| G&A Expenses | $62,480 | $31,400 | $28,202 | $28,717 |
| SG&A Expenses | $62,480 | $31,400 | $28,202 | $28,717 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2,243 | -$2,461 | $0 | $0 |
| Operating Expenses | $341,643 | $239,701 | $170,962 | $150,025 |
| Operating Income | -$343,886 | -$242,162 | -$170,962 | -$150,025 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $26,468 | $6,225 | $2,863 | $734 |
| Pre-Tax Income | -$317,418 | -$235,937 | -$168,099 | -$149,291 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$317,418 | -$235,937 | -$168,099 | -$149,291 |
| % Margin | – | – | – | – |
| EPS | -3.37 | -3.95 | -3.23 | -2.93 |
| % Growth | 14.7% | -22.3% | -10.2% | – |
| EPS Diluted | -3.37 | -3.95 | -3.23 | -2.93 |
| Weighted Avg Shares Out | 94,144 | 59,684 | 51,976 | 50,895 |
| Weighted Avg Shares Out Dil | 94,144 | 59,684 | 51,976 | 50,895 |
| Supplemental Information | – | – | – | – |
| Interest Income | $26,922 | $7,641 | $2,917 | $742 |
| Interest Expense | $0 | $0 | $2,917 | $0 |
| Depreciation & Amortization | $2,243 | $2,461 | $1,683 | $1,088 |
| EBITDA | -$315,175 | -$233,476 | -$169,279 | -$148,937 |
| % Margin | – | – | – | – |